 |
|
Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma
Hyo Jin Seong, Kwanghyun Lee, Seung Jae Lee, Sangah Kim, Jong Woon Park
Korean J Ophthalmol. 2021;35(3):235-241. Published online 2021 Jun 4 DOI: https://doi.org/10.3341/kjo.2021.0010
|
|
Citations to this article as recorded by
 Ocular Surface Disease in Glaucoma Patients
Christina Scelfo, Reem H. ElSheikh, Muhammad M. Shamim, Javaneh Abbasian, Alireza Ghaffarieh, Abdelrahman M. Elhusseiny
Current Eye Research.2023; 48(3): 219. CrossRef The molecular aspect of anti-glaucomatous eye drops - are we harming our patients?
Anne Hedengran, Miriam Kolko
Molecular Aspects of Medicine.2023; 93: 101195. CrossRef Initial hypotensive therapy of primary glaucoma with the domestic latanoprost generic: efficacy and safety
S. Yu. Petrov, O. M. Kalinina, L. V. Yakubova, S. M. Kosakyan, L. V. Vasilenkova, O. M. Filippova, A. N. Zhuravleva
Russian Ophthalmological Journal.2022; 14(4): 7. CrossRef Topical glaucoma medications – Clinical implications for the ocular surface
Fredrik Fineide, Neil Lagali, Muhammed Yasin Adil, Reiko Arita, Miriam Kolko, Jelle Vehof, Tor P. Utheim
The Ocular Surface.2022; 26: 19. CrossRef Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis
Jong-Wook Lee, Hyeon-Soo Ahn, Jinho Chang, Hye-Young Kang, Dong-Jin Chang, Jae Kyung Suh, Hankil Lee
Korean Journal of Ophthalmology.2022; 36(5): 423. CrossRef
|